|
Cutaneous Melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Oncogenic mutations in c-KIT, NRAS and BRAF components of the MAPK pathway have been identified in nearly 90% of cutaneous melanoma and this information has been used to develop small molecules that inhibit their activity.
|
29061773 |
2017 |
|
Cutaneous Melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Putative genomic characteristics of BRAF V600K versus V600E cutaneous melanoma.
|
28858076 |
2017 |
|
Cutaneous Melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Vemurafenib and dabrafenib, two Food and Drug Administration-approved selective BRAF kinase inhibitors (BRAFi), have revolutionized the targeted therapy of cutaneous melanoma.
|
28252478 |
2017 |
|
Cutaneous Melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Seventy-eight cases of CN involving SLN of PCM patients were evaluated for BRAF V600E mutation by IHC.
|
27666765 |
2017 |
|
Cutaneous Melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The development of cutaneous melanoma is influenced by genetic factors, including BRAF mutations and environmental factors, such as ultraviolet exposure.
|
28075446 |
2017 |
|
Cutaneous Melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Hotspot mutations of the oncogenes BRAF and NRAS are the most common genetic alterations in cutaneous melanoma.
|
28797232 |
2017 |
|
Cutaneous Melanoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Many new treatment options in the last years, in particular targeted therapies (i.e. inhibitors of c-KIT, NRAS/MEK or BRAF) and immunotherapies (anti CTLA-4 and anti PD-1/PD-L1 antibodies), have changed the history of cutaneous melanoma.
|
28325255 |
2017 |
|
Cutaneous Melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Among 41 response-evaluable patients, 2 (5 %) patients with cutaneous melanoma (one with BRAF L597R mutant melanoma) had partial responses.
|
27650277 |
2017 |
|
Cutaneous Melanoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
BRAF and Epithelial-Mesenchymal Transition: Lessons From Papillary Thyroid Carcinoma and Primary Cutaneous Melanoma.
|
27145091 |
2016 |
|
Cutaneous Melanoma
|
0.500 |
GeneticVariation
|
disease |
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
|
Cutaneous Melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Aquaporin 1 protein expression is associated with BRAF V600 mutation and adverse prognosis in cutaneous melanoma.
|
26848795 |
2016 |
|
Cutaneous Melanoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
We sought to elucidate the relationship between BRAF, Snail, E-cadherin, and established histopathologic prognosticators in primary cutaneous melanoma.
|
26980024 |
2016 |
|
Cutaneous Melanoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
To our knowledge, this is the first reported case of paraneoplastic neurological syndrome with mixed neurology associated with BRAF mutant cutaneous melanoma that responded to BRAF targeted therapy.
|
27138260 |
2016 |
|
Cutaneous Melanoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Oncogenic BRAF induces chronic ER stress condition resulting in increased basal autophagy and apoptotic resistance of cutaneous melanoma.
|
25361077 |
2015 |
|
Cutaneous Melanoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
We observed that both PDK 1 and 2 isoforms are overexpressed in CM compared to nevi, this expression being associated with the expression of the mTOR pathway effectors and independent of the BRAF mutational status.
|
25976231 |
2015 |
|
Cutaneous Melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Coexistence of TERT promoter and BRAF mutations in cutaneous melanoma is associated with more clinicopathological features of aggressiveness.
|
26055532 |
2015 |
|
Cutaneous Melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Notably, common BRAF and NRAS mutations in cutaneous melanoma are associated with increased miR-21 expression.
|
26116372 |
2015 |
|
Cutaneous Melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The BRAF V600E mutation accounts for the majority of BRAF mutations found in cutaneous melanoma and is also commonly found in nevi.
|
25607474 |
2015 |
|
Cutaneous Melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Comparison between two widely used laboratory methods in BRAF V600 mutation detection in a large cohort of clinical samples of cutaneous melanoma metastases to the lymph nodes.
|
26339422 |
2015 |
|
Cutaneous Melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Russian study of morphological prognostic factors characterization in BRAF-mutant cutaneous melanoma.
|
25888143 |
2015 |
|
Cutaneous Melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
BRAF mutations are present in 40% of human skin melanomas.
|
26141748 |
2015 |
|
Cutaneous Melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Cutaneous malignant melanoma is the leading cause of death from skin diseases and is often associated with activating mutations of the proto-oncogene BRAF.
|
25174976 |
2015 |
|
Cutaneous Melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We sought to further evaluate the prognostic value of BRAF mutations in localized cutaneous melanoma.
|
24388723 |
2014 |
|
Cutaneous Melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The present study investigated the BRAF V600E mutation frequency and its clinical implications in a group of 77 primary cutaneous melanoma patients treated in a cancer reference center in Brazil.
|
24535907 |
2014 |
|
Cutaneous Melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The purpose of this study is to describe a case of concurrent medullary and papillary thyroid carcinoma (MTC and PTC) and cutaneous melanoma and to analyze BRAF(V600E) mutation in plasma and tissues.
|
24858900 |
2014 |